A Potent Target for Cancer Treatment – Tumor Hypoxia Necrosis: An Overview
Keywords:
Cancer Treatment, Tumor Hypoxia Necrosis, tumor selective treatment
Abstract
Tumor hypoxia is feature of locally advancing solid tumor and also considered as potential therapeutic challenge. It causes solid tumor resistible to the cancer treatment like radiation and chemotherapeutic drugs. The transcription factor HIF-1 is the major player in the regulation of tumor progression into malignant phenotype. We can target this hypoxic conditions using pathophysiological approach for targeted drug delivery for treatment of cancer. This review will focus on various biological aspects of tumor hypoxia necrosis and approaches for targeting hypoxic tumors. This tumor selective treatment will include bioreductive drugs, gene therapy, and recombinant bacteria.
References
1.Brown, J. M.; Wilson, W. R. Exploiting Tumour Hypoxia in Cancer Treatment. Nat. Rev. Cancer 2004, 4, 437–447.
2.Chao, K. S.; Bosch, W. R.; Mutic, S.; Lewis, J. S.; Dehdashti, F.; Mintun, M. a; Dempsey, J. F.; Perez, C. a; Purdy, J. a; Welch, M. J. A Novel Approach to Overcome Hypoxic Tumor Resistance: Cu-ATSM-Guided Intensity-Modulated Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 1171–1182.
3.DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W. Hypoxia Regulates TSC1/2-mTOR Signaling and Tumor Suppression through REDD1-Mediated 14-3-3 Shuttling. Genes Dev. 2008, 22, 239–251.
4.Garayoa, M.; Mart?, A.; Lee, S.; An, W. G.; Neckers, L.; Trepel, J.; Montuenga, L. M.; Ryan, H.; Johnson, R.; Gassmann, M. Expression in Human Tumor Cell Lines during Oxygen Deprivation?: A Possible Promotion Mechanism of Carcinogenesis. 2014, 1, 848–862.
5.Kizaka-Kondoh, S.; Inoue, M.; Harada, H.; Hiraoka, M. Tumor Hypoxia: A Target for Selective Cancer Therapy. Cancer Sci. 2003, 94, 1021–1028.
6.Koong, a C.; Mehta, V. K.; Le, Q. T.; Fisher, G. a; Terris, D. J.; Brown, J. M.; Bastidas, a J.; Vierra, M. Pancreatic Tumors Show High Levels of Hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 919–922.
7.Lewis, C. E.; Pollard, J. W. Distinct Role of Macrophages in Different Tumor Microenvironments. Cancer Res. 2006, 66, 605–612.
8.Park, J. E.; Tan, H. Sen; Datta, A.; Lai, R. C.; Zhang, H.; Meng, W.; Lim, S. K.; Sze, S. K. Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes. Mol. Cell. Proteomics 2010, 9, 1085–1099.
9.Sutherland, R. M. Tumor Hypoxia and Gene Expression--Implications for Malignant Progression and Therapy.ActaOncol. 1998, 37, 567–574.
10.Vaupel, P. The Role of Hypoxia-Induced Factors in Tumor Progression. Oncologist 2004, 9 Suppl 5, 10–17.
11.Wilson, W. R.; Hay, M. P. Targeting Hypoxia in Cancer Therapy. Nat. Rev. Cancer 2011, 11, 393–410.
12.Garayoa, M.; Mart?, A.; Lee, S.; An, W. G.; Neckers, L.; Trepel, J.; Montuenga, L. M.; Ryan, H.; Johnson, R.; Gassmann, M. Expression in Human Tumor Cell Lines during Oxygen Deprivation?: A Possible Promotion Mechanism of Carcinogenesis. 2014, 1, 848–862.
13.Groshar, D.; McEwan, a J.; Parliament, M. B.; Urtasun, R. C.; Golberg, L. E.; Hoskinson, M.; Mercer, J. R.; Mannan, R. H.; Wiebe, L. I.; Chapman, J. D. Imaging Tumor Hypoxia and Tumor Perfusion. J. Nucl. Med. 1993, 34, 885–888.
14.Harrison, L. B. Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist 2002, 7, 492–508.
15.Kizaka-Kondoh, S.; Inoue, M.; Harada, H.; Hiraoka, M. Tumor Hypoxia: A Target for Selective Cancer Therapy. Cancer Sci. 2003, 94, 1021–1028.
16.Koong, a C.; Mehta, V. K.; Le, Q. T.; Fisher, G. a; Terris, D. J.; Brown, J. M.; Bastidas, a J.; Vierra, M. Pancreatic Tumors Show High Levels of Hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 919–922.
17.Lewis, C. E.; Pollard, J. W. Distinct Role of Macrophages in Different Tumor Microenvironments. Cancer Res. 2006, 66, 605–612.
18.Liao, D.; Corle, C.; Seagroves, T. N.; Liao, D.; Corle, C.; Seagroves, T. N.; Johnson, R. S. Hypoxia-Inducible Factor-1 Α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression Transgenic Model of Cancer Initiation and Progression. 2007, 563–572.
19.Maxwell, P. H.; Dachs, G. U.; Gleadle, J. M.; Nicholls, L. G.; Harris, a L.; Stratford, I. J.; Hankinson, O.; Pugh, C. W.; Ratcliffe, P. J. Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 8104–8109.
20.Robey, I. F.; Lien, A. D.; Welsh, S. J.; Baggett, B. K.; Gillies, R. J. Hypoxia-Inducible Factor-1α and the Glycolytic Phenotype in Tumors. Neoplasia 2005, 7, 324–330.
21.Schwab, L. P.; Peacock, D. L.; Majumdar, D.; Ingels, J. F.; Jensen, L. C.; Smith, K. D.; Cushing, R. C.; Seagroves, T. N. Hypoxia-Inducible Factor 1α Promotes Primary Tumor Growth and Tumor-Initiating Cell Activity in Breast Cancer. Breast Cancer Res. 2012, 14, R6.
22.Shahrzad, S.; Bertrand, K.; Minhas, K.; Coomber, B. L. Induction of DNA Hypomethylation by Tumor Hypoxia. Epigenetics 2007, 2, 119–125.
23.Sutherland, R. M. Tumor Hypoxia and Gene Expression--Implications for Malignant Progression and Therapy. ActaOncol. 1998, 37, 567–574.
24.Unruh, A.; Ressel, A.; Mohamed, H. G.; Johnson, R. S.; Nadrowitz, R.; Richter, E.; Katschinski, D. M.; Wenger, R. H. The Hypoxia-Inducible Factor-1 Alpha Is a Negative Factor for Tumor Therapy. Oncogene 2003, 22, 3213–3220.
25.Vordermark, D.; Kraft, P.; Katzer, A.; Bölling, T.; Willner, J.; Flentje, M. Glucose Requirement for Hypoxic Accumulation of Hypoxia-Inducible Factor-1alpha (HIF-1alpha). Cancer Lett. 2005, 230, 122–133.
26.Wilson, W. R.; Hay, M. P. Targeting Hypoxia in Cancer Therapy. Nat. Rev. Cancer 2011, 11, 393–410.
27.Zhdanov, A. V; Dmitriev, R. I.; Golubeva, A. V; Gavrilova, S. a; Papkovsky, D. B. Chronic Hypoxia Leads to a Glycolytic Phenotype and Suppressed HIF-2 Signaling in PC12 Cells. Biochim.Biophys.Acta 2013, 1830, 3553–3569.
2.Chao, K. S.; Bosch, W. R.; Mutic, S.; Lewis, J. S.; Dehdashti, F.; Mintun, M. a; Dempsey, J. F.; Perez, C. a; Purdy, J. a; Welch, M. J. A Novel Approach to Overcome Hypoxic Tumor Resistance: Cu-ATSM-Guided Intensity-Modulated Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 1171–1182.
3.DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W. Hypoxia Regulates TSC1/2-mTOR Signaling and Tumor Suppression through REDD1-Mediated 14-3-3 Shuttling. Genes Dev. 2008, 22, 239–251.
4.Garayoa, M.; Mart?, A.; Lee, S.; An, W. G.; Neckers, L.; Trepel, J.; Montuenga, L. M.; Ryan, H.; Johnson, R.; Gassmann, M. Expression in Human Tumor Cell Lines during Oxygen Deprivation?: A Possible Promotion Mechanism of Carcinogenesis. 2014, 1, 848–862.
5.Kizaka-Kondoh, S.; Inoue, M.; Harada, H.; Hiraoka, M. Tumor Hypoxia: A Target for Selective Cancer Therapy. Cancer Sci. 2003, 94, 1021–1028.
6.Koong, a C.; Mehta, V. K.; Le, Q. T.; Fisher, G. a; Terris, D. J.; Brown, J. M.; Bastidas, a J.; Vierra, M. Pancreatic Tumors Show High Levels of Hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 919–922.
7.Lewis, C. E.; Pollard, J. W. Distinct Role of Macrophages in Different Tumor Microenvironments. Cancer Res. 2006, 66, 605–612.
8.Park, J. E.; Tan, H. Sen; Datta, A.; Lai, R. C.; Zhang, H.; Meng, W.; Lim, S. K.; Sze, S. K. Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes. Mol. Cell. Proteomics 2010, 9, 1085–1099.
9.Sutherland, R. M. Tumor Hypoxia and Gene Expression--Implications for Malignant Progression and Therapy.ActaOncol. 1998, 37, 567–574.
10.Vaupel, P. The Role of Hypoxia-Induced Factors in Tumor Progression. Oncologist 2004, 9 Suppl 5, 10–17.
11.Wilson, W. R.; Hay, M. P. Targeting Hypoxia in Cancer Therapy. Nat. Rev. Cancer 2011, 11, 393–410.
12.Garayoa, M.; Mart?, A.; Lee, S.; An, W. G.; Neckers, L.; Trepel, J.; Montuenga, L. M.; Ryan, H.; Johnson, R.; Gassmann, M. Expression in Human Tumor Cell Lines during Oxygen Deprivation?: A Possible Promotion Mechanism of Carcinogenesis. 2014, 1, 848–862.
13.Groshar, D.; McEwan, a J.; Parliament, M. B.; Urtasun, R. C.; Golberg, L. E.; Hoskinson, M.; Mercer, J. R.; Mannan, R. H.; Wiebe, L. I.; Chapman, J. D. Imaging Tumor Hypoxia and Tumor Perfusion. J. Nucl. Med. 1993, 34, 885–888.
14.Harrison, L. B. Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist 2002, 7, 492–508.
15.Kizaka-Kondoh, S.; Inoue, M.; Harada, H.; Hiraoka, M. Tumor Hypoxia: A Target for Selective Cancer Therapy. Cancer Sci. 2003, 94, 1021–1028.
16.Koong, a C.; Mehta, V. K.; Le, Q. T.; Fisher, G. a; Terris, D. J.; Brown, J. M.; Bastidas, a J.; Vierra, M. Pancreatic Tumors Show High Levels of Hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 919–922.
17.Lewis, C. E.; Pollard, J. W. Distinct Role of Macrophages in Different Tumor Microenvironments. Cancer Res. 2006, 66, 605–612.
18.Liao, D.; Corle, C.; Seagroves, T. N.; Liao, D.; Corle, C.; Seagroves, T. N.; Johnson, R. S. Hypoxia-Inducible Factor-1 Α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression Transgenic Model of Cancer Initiation and Progression. 2007, 563–572.
19.Maxwell, P. H.; Dachs, G. U.; Gleadle, J. M.; Nicholls, L. G.; Harris, a L.; Stratford, I. J.; Hankinson, O.; Pugh, C. W.; Ratcliffe, P. J. Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 8104–8109.
20.Robey, I. F.; Lien, A. D.; Welsh, S. J.; Baggett, B. K.; Gillies, R. J. Hypoxia-Inducible Factor-1α and the Glycolytic Phenotype in Tumors. Neoplasia 2005, 7, 324–330.
21.Schwab, L. P.; Peacock, D. L.; Majumdar, D.; Ingels, J. F.; Jensen, L. C.; Smith, K. D.; Cushing, R. C.; Seagroves, T. N. Hypoxia-Inducible Factor 1α Promotes Primary Tumor Growth and Tumor-Initiating Cell Activity in Breast Cancer. Breast Cancer Res. 2012, 14, R6.
22.Shahrzad, S.; Bertrand, K.; Minhas, K.; Coomber, B. L. Induction of DNA Hypomethylation by Tumor Hypoxia. Epigenetics 2007, 2, 119–125.
23.Sutherland, R. M. Tumor Hypoxia and Gene Expression--Implications for Malignant Progression and Therapy. ActaOncol. 1998, 37, 567–574.
24.Unruh, A.; Ressel, A.; Mohamed, H. G.; Johnson, R. S.; Nadrowitz, R.; Richter, E.; Katschinski, D. M.; Wenger, R. H. The Hypoxia-Inducible Factor-1 Alpha Is a Negative Factor for Tumor Therapy. Oncogene 2003, 22, 3213–3220.
25.Vordermark, D.; Kraft, P.; Katzer, A.; Bölling, T.; Willner, J.; Flentje, M. Glucose Requirement for Hypoxic Accumulation of Hypoxia-Inducible Factor-1alpha (HIF-1alpha). Cancer Lett. 2005, 230, 122–133.
26.Wilson, W. R.; Hay, M. P. Targeting Hypoxia in Cancer Therapy. Nat. Rev. Cancer 2011, 11, 393–410.
27.Zhdanov, A. V; Dmitriev, R. I.; Golubeva, A. V; Gavrilova, S. a; Papkovsky, D. B. Chronic Hypoxia Leads to a Glycolytic Phenotype and Suppressed HIF-2 Signaling in PC12 Cells. Biochim.Biophys.Acta 2013, 1830, 3553–3569.
Published
2014-07-01
How to Cite
[1]
Patil, P. and Tayade, R. 2014. A Potent Target for Cancer Treatment – Tumor Hypoxia Necrosis: An Overview. PharmaTutor. 2, 7 (Jul. 2014), 8-28.
Section
Articles
